ライフサイエンスコーパス: complement C3

1 us is dependent on innate immunity component complement C3.

2 inhibitors that bind and inhibit cleavage of complement C3.

3 lement regulators, and direct degradation of complement C3.

4 sing the expression and bacterial binding of complement C3.

5 ccus aureus protein that engages host Fg and complement C3.

6 their PNH erythrocytes become opsonized with complement C3.

7 o, processes strictly dependent on Mac-1 and complement C3.

8 We investigated whether complement C3, a central component, affects synapse loss

9 qa, factor B, and factor B/C2, we found that complement C3 activation and opsonophagocytosis of S. pn

10 membrane complement regulator that inhibits complement C3 activation by both classical and alternati

11 Complement C3 activation is a characteristic finding in

12 In our previous studies we showed that the complement C3 activation peptide, C3a, sensitizes respon

13 The ligation of the complement C3 activation product iC3b to complement rece

14 ike factor H, a potent negative regulator of complement C3 activation, the FHR proteins appear to pro

15 Following therapeutic inhibition of complement C3 activation, we found reduced myocardial up

16 Thus, complement C3 allows cells to detect and disable pathoge

17 The role of mast cells, complement (C3 and C5a), and CD18 integrins in FcgammaRI

18 dy [ANA] and anti-double-stranded (ds) DNA), complement C3 and C4, and changes in renal and pulmonary

19 teases that carry the catalytic sites of the complement C3 and C5 convertases.

20 ologically active fragments derived from the complement C3 and C5 family of proteins.

21 (FcgammaRs), particularly FcgammaRIII, with complement C3 and C5 having no detectable role.

22 n the current study, we examined the role of complement C3 and C5 in sepsis in wild-type and C3- or C

23 lected periplakin, envoplakin, villin-1, and complement C3 and C9 for confirmation because they were

24 Genetic deficiency of complement C3 and factor D prevented both the systemic t

25 preventing interference by the glycoprotein complement C3 and its beta-globulin split products in th

26 evealed an additional novel pathway in which complement C3 and its receptors enhance humoral immunity

27 ore, gut dysbiosis induces the expression of complement C3 and production of the anaphylatoxin C3a, a

28 s nonhematopoietic in origin, independent of complement C3 and the adaptive immune system, mitigated

29 rostatic potential based on 24 homologues of complement C3d and 4 homologues of CR2.

30 CR2 ligands include complement C3d and Epstein-Barr virus glycoprotein 350/2

31 R-16/20 fragment possesses binding sites for complement C3d and heparin.

32 identify molecules with predicted binding to complement C3d and with intrinsic fluorescence propertie

33 um complement (C3), neointimal deposition of complement (C3d), and cellular composition (monocytes, m

34 of estrogen-responsive genes including pS2, complement C3, and progesterone receptor.

35 ubset markers and for the third component of complement, C3, and membrane attack complex deposition.

36 19-CD21 cell surface receptor complex, where complement C3d binding to CD21 supplies an already chara

37 ion of the B cell Ag receptor (BCR) with the complement (C3)-binding CD21/CD19/CD81 costimulatory com

38 ther the potential of an Ag to co-ligate the complement (C3d)-binding CD21 receptor complex with the

39 mice lacking Fcgamma receptors (FcgammaRs), complement (C3), both, or none.

40 Transgenic mice exhibited lower plasma complement C3 but increased deposition of CRP and C3 in

41 Altering the electrophoretic behavior of complement C3, by treating fresh serum with inulin, perm

42 spiratory morbidity, growth, and anxiety and complement C3, C-reactive protein, serum cortisol, trans

43 l antibody (MAb) to type 3 capsule increases complement C3, C1q, and C4 deposition on WU2 and enhance

44 ment factor I (CFI), complement C9 (C9), and complement C3 (C3) genes.

45 alpha1-antitrypsin [SERPINA1], 2.5-fold; and complement C3 [C3], 2.3-fold) and 5 were found to be dow

46 Covalent attachment of activated complement C3 (C3d) to antigen links innate and adaptive

47 tistically significant improvements in serum complement C3, C4, and anti-double-stranded DNA (anti-ds

48 imed at testing this idea for the paralogous complement C3, C4, and C5 proteins.

49 Levels of complement C3, C4, and CH50 and titers of anti-double-st

50 B cell memory response of mice deficient in complement C3, C4, or CD21/CD35 with wild-type controls.

51 owth factor beta, chemokine CCL2, SDF-1, and complements C3, C4, and factor B (CFB), were examined by

52 ncreases in immunoglobulin (IgM and IgG) and complement (C3, C4d, and C5b-9) deposition, as well as w

53 teinuria levels correlated with staining for complement (C3, C5b-9) and IgG1 isotype in glomerular im

54 Complement C3 cleavage products mediate the recognition

55 ophages capable of increased phagocytosis of complement C3-coated particles, a function critical for

56 lysis or fibrinogen, C-reactive protein, and complement C3) confirmed that denser clots are independe

57 gents that target the alternative pathway of complement C3 convertase are being developed with a goal

58 d a complex on the T. cruzi surface with the complement C3 convertase, leading to its stabilization a

59 y included lipid transfer inhibitor protein, complement C3d, corticosteroid-binding globulin, apolipo

60 This study explored complement C3 deficiency in mice and human subjects for

61 storation of virulence of the lctP mutant in complement (C3(-/-))-deficient animals.

62 control C57BL/6 (n=30) mice and into eyes of complement (C3)-deficient (n=15) or wild-type control 12

63 Following induction of BD in complement (C3)-deficient mice, cardiac troponin levels,

64 e role of C3 in AD pathology, we generated a complement C3-deficient amyloid precursor protein (APP)

65 Complement C3-deficient mice also had significantly decr

66 ated systemic LPS application was rescued in complement C3-deficient mice, confirming the involvement

67 - and Rac-independent pathways promote Mac-1/complement C3-dependent functions.

68 D18 integrin Mac-1 on neutrophils recognized complement C3 deposited within vessel walls and triggere

69 e mice had an increase in tubulointerstitial complement C3 deposition and neutrophil infiltration in

70 mmaRI-PspA-immunized Tg mice showed enhanced complement C3 deposition on bacterial surfaces, and prot

71 rocytes to macrophages are both dependent on complement C3 deposition onto the pneumococcal surface.

72 The enhanced complement C3 deposition realized in the absence of PspA

73 PC, and CRP binding to pneumococci enhances complement C3 deposition through the classical pathway.

74 Complement C3 deposition was greatly attenuated in heart

75 dditionally, histopathology scores and total complement C3 deposition were significantly lower in Cl-

76 the K1 capsule, an increase in the level of complement C3 deposition, and an increase in both opsoni

77 ascular cellular infiltration; IgG, IgM, and complement (C3) deposition; vascular cell injury and int

78 Ab and complement (C3d) deposition was accompanied by extensive

79 Complement (C3d) deposition was diffuse and prominent in

80 a have revealed that ASP is identical to the complement C3-derived activation peptide C3ades-Arg.

81 5) with human serum results in deposition of complement C3-derived polypeptides on virion particles.

82 The role of the third component of complement (C3) during schistosome infection was investi

83 receptor that binds three distinct ligands (complement C3d, Epstein-Barr virus gp350/220, and the lo

84 PASP was found to degrade complement C3, fibrinogen, antimicrobial peptide LL-37,

85 complexes, and glomerular deposition of IgA, complement C3, Fn and collagen.

86 omplement receptor type 2 (CR2) that bind to complement C3d, followed by the first five SCR domains o

87 to intercellular adhesion molecule (ICAM)-1, complement C3 fragment iC3b, and fibronectin, and potent

88 on MCF7 inhibited the in vivo deposition of complement C3 fragments that serve as opsonins for recep

89 ly recognize and respond to antigens bearing complement C3d(g).

90 e located on the sense DNA strand within the complement C3 gene locus which is encoded on the antisen

91 The analysis of the human complement C3 gene reveals the presence of functional FX

92 ts carrying the same mutation, R139W, in the complement C3 gene.

93 The expression of complement C3 (>5-fold) and CFB (>30-fold) genes in the

94 ns of the activating components factor B and complement C3 have also been reported.

95 emonstrate that the majority of mutations in complement C3 identified in atypical hemolytic uremic sy

96 ciated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.

97 following IOP elevation is up-regulation of complement C3 in astrocytes of DBA/2J and DBA/2J.Wld(s)

98 study, our goal was to ascertain the role of complement C3 in autoimmune diabetes.

99 The role of complement C3 in mediating systemic lupus erythematosus

100 Our results suggest a beneficial role for complement C3 in plaque clearance and neuronal health as

101 The presence of complement C3 in serum promoted phagocytosis, yet phagos

102 ermined deficiency of the third component of complement (C3) in the dog is characterized by a predisp

103 Enhanced complement C3 incorporation into the fibrin network in d

104 Ib and bacterial opsonization with activated complement C3, influences blood clearance and anti-infec

105 ta support the strategy of using recombinant complement C3 inhibitors to treat human lupus nephritis.

106 ition, pathogens carried covalently attached complement C3 into the cell, triggering immediate signal

107 Complement C3 is a pivotal component of three cascades o

108 Complement C3 is a pivotal component of three cascades o

109 Complement C3 is important for the classical, alternativ

110 Complement C3 is important in the pathogenesis of age-re

111 , the functionally active third component of complement (C3) is encoded by a single gene.

112 The third component of complement, C3, is a point of convergence of distinct co

113 ion, the chemokines CXCL1, CXCL5, CXCL6, and complement C3, known to contribute to chronic inflammati

114 % used either the anti-DNA antibody level or complement C3 level to monitor patients with SLE, and 95

115 m hemolytic complement (CH(50)) activity and complement C3 levels during infection, and serum opsonic

116 erminal center formation and decreased serum complement C3 levels.

117 ctive target at or near the TEP1 gene, whose complement C3-like product has antiparasitic and antibac

118 The complex interacts with the complement C3-like protein, TEP1, promoting its cleavage

119 Levels of serum complement (C3), neointimal deposition of complement (C3

120 characterized by electron-dense deposits and complement C3 on the glomerular basement membrane.

121 and antibodies to PspA on the deposition of complement C3 on the surface of a capsular type 3 strain

122 ed for efficient binding and phagocytosis of complement C3-opsonized particles.

123 ciency in IL-34 production) or deficiency in complement C3 or C3a receptor were protected from WNV-in

124 A trend toward normal complement C3 or C4 level at week 26 was seen in the sif

125 Genetic ablation of complement C3 or its inactivation with Cobra Venom Facto

126 t mutant in regard to avid binding by murine complement C3 or resistance to serum- or whole-blood-med

127 Our results suggest that complement C3, or its downstream signaling, is detriment

128 ificantly decreased alpha2-macroglobulin and complement C3, P < 0.05.

129 of transcripts for the APPs serum amyloid A, complement C3, pentraxin 3, and alpha2-antiplasmin in th

130 The third component of human complement (C3) plays a central role in innate immune fu

131 P-2.DNA complex formation, and for the human complement C3 promoter, overexpression of AP-2 also coul

132 We evaluated complement C3 protein deposition on discordant S. pneumo

133 t an increase in the plasma concentration of complement C3 protein.

134 ntified a 20-kDa protein with putative human complement C3-proteolytic activity.

135 CRIg is a recently discovered complement C3 receptor expressed on a subpopulation of t

136 Ig superfamily (CRIg), a recently discovered complement C3 receptor.

137 ic complement pathway despite an increase in complement C3 regulatory proteins.

138 of the process by detecting the presence of complement C3, SHC-transforming protein 1, and kininogen

139 Peritubular complement C3d staining was also similar in both groups.

140 us pneumoniae to bind the third component of complement (C3) suggests possible interactions with opso

141 Using this method, we found that anti-complement C3-targeted ultrasmall superparamagnetic iron

142 posure resulted in production and release of complement C3, the generation of C3a, oxidative stress,

143 get pathological neovasculature and activate complement (C3), thereby inducing neovascularitis, infil

144 Disease activity scores, complement C3 tissue deposition in the joint, and histop

145 and decreasing the third component of serum complement (C3) to be associated with increasing glomeru

146 inear deposits of immunoglobulin G (IgG) and complement C3, typical of anti-glomerular basement membr

147 alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinas

148 In addition, mouse complement (C3) was detected on xenografted PI.

149 ns capable of binding the third component of complement (C3), we coupled the free sulfhydryl group of

150 Furthermore, mice deficient in complement C3 were resistant to fetal injury induced by

151 d an adjuvant effect for the C3d fragment of complement C3 when coupled to T-dependent protein antige

152 ppa B (NF-kappaB), leading to the release of complement C3, which acts on the neuronal C3a receptor (